Navigation Links
Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date:11/1/2011

PALO ALTO, Calif., Nov. 1, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today the presentation of mechanistic studies on Telintra and related analogs at the 2011 Meeting of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California.  Details of the presentation are as follows:


  • Novel Ezatiostat analogues disrupt binding of GSTP1 to all three major MAP kinases (JNK, ERK and p38) and exhibit context-dependent antitumor activity; Ali-Osman, F., Okamura, T., Turley, R., Barker, A.,  Keck, J.,  Laborde, E.,  Cai, D.,  Macsata, R.Abstract B229 – PO 70, Therapeutic Agents: Small Molecule Kinase Inhibitors 2, Monday, November 14, 12:30-2:30 PM and 6:00-7:30 PM.These studies were conducted by Professor Francis Ali-Osman, Director, Experimental Therapeutics Program, Duke Comprehensive Cancer Center, and expand our understanding of the novel mechanism of action of Telintra.  Telintra and related analogues, through their inhibition of the enzyme GSTP1, were able to affect the activity of all three major MAP kinases, signaling proteins that are critical for the control of cellular growth, differentiation and apoptosis.  Significant anti-tumor activity was also observed in human cancer cells derived from brain cancer, breast cancer and melanoma.  Telintra has demonstrated positive clinical activity in patients with myelodysplastic syndrome (Blood 2009, 113[26]:6533-6540; Cancer 2011, doi: 10.1002/cncr.26469), and is currently in clinical development (Clintrials.gov).

    About Telik

    Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

    Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


    '/>"/>

  • SOURCE Telik, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
    2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
    3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
    4. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
    5. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
    6. Telik Announces Presentation at ASCO Annual Meeting
    7. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
    8. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
    9. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
    10. Telik Announces Third Quarter 2009 Financial Results
    11. Telik Announces Fourth Quarter and 2009 Year End Financial Results and 2010 Financial Guidance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE ... team that developed an innovative way to use nonlinear ... the delivery of new drugs. ... Clinical Dermatology Conference will show how researchers from BioPharmX ... Harvard Medical School used a suite of imaging techniques ...
    (Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
    (Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
    (Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
    (Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
    (Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
    (Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
    Breaking Medicine News(10 mins):